Casein kinase 2 inhibitor, CX-4945, as a potential targeted anticancer agent in gastric cancer

Hyun Myong Kim, Inhye Jeong, Hyun Jeong Kim, Sun Kyoung Kang, Woo Sun Kwon, Tae Soo Kim, Kyu Hyun Park, Minkyu Jung, John Soong, Shu Chuan Lin, Hyun Cheol Chung, Sun Young Rha

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Background/Aim: Casein kinase 2 (CK2) is involved in multiple cellular processes. Furthermore, its overexpression in several human cancers has been associated with tumor progression. In this study, we evaluated the efficacy of the CK2 inhibitor, CX-4945, in gastric cancer cell lines and explored the potential predictive biomarkers for CX-4945 sensitivity. Materials and Methods: The sensitivity to CX-4945 was screened in 49 gastric cancer cell lines by the MTT assay. The mRNA and protein expression of CK2 subunits (α and α') were determined using qRT-PCR and western blot. Furthermore, the activity of CK2α was measured by ELISA. Gene expression and mutations were analyzed via whole-exome and RNA sequencing. Results: The sensitivity to CX-4945 was determined by the inhibition rate (%) at the effective dose (10 μM) which ranged from -1% to 89% in 49 gastric cancer cell lines. CK2α', but not CK2α, mRNA expression was correlated with CX-4945 sensitivity. Conclusion: In this study, CX-4945 showed modest antitumor efficacy in gastric cancer cell lines. CK2 might represent a potential therapeutic target for gastric cancer.

Original languageEnglish
Pages (from-to)6171-6180
Number of pages10
JournalAnticancer research
Issue number11
Publication statusPublished - 2018 Nov

Bibliographical note

Publisher Copyright:
© 2018 International Institute of Anticancer Research.All right reserved.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Casein kinase 2 inhibitor, CX-4945, as a potential targeted anticancer agent in gastric cancer'. Together they form a unique fingerprint.

Cite this